-
10:25:55 PM
Trending News

Covid-19 News LIVE

The stock market news feed is automatically updated to show the latest 50 news.
The news is in real time for GOLD users while a 15 second delay is applied for FREE users.

Become a Gold member to unlock the feed filters, voice notification and see the news without delay.

Check out our Stock Market News Today and Join our Discord

12/01/22 2:30 AM
Nasdaq : BPTS
clinical trialcovid-19low float
Biophytis Organises a Webcast with Key Opinion Leaders (KOL) On the Phase 2-3 Cova Study Results of Sarconeos (Bio101) In the Treatment of Pneumonia in Covid-19 Patients at Risk of Respiratory Failure
Following the positive post-hoc analysis of the phase 2-3 COVA clinical study strongly supporting therapeutic potential of Sarconeos (BIO101) in the treatment of pneumonia in COVID-19 patients at risk of repiratory failure, Biophytis management is inviting all of Biophytis' stakeholders to an
RHEA-AI
negative
11/29/22 2:06 PM
Nasdaq : SRNE
clinical trialcovid-19
Sorrento Releases Positive Topline Results from the Phase I Study Completed in Australia and Preliminary Results from a Phase Ib Study in China with STI-1558, an Oral M(pro) Inhibitor as a Standalone Treatment for COVID-19 without the Need for Ritonavir Boosting
Topline safety and pharmacokinetic (PK) data from the Phase I single ascending dose (SAD)/multiple ascending dose (MAD) study of STI-1558 in 58 healthy volunteers in Australia are now available. The SAD portion of the study evaluated doses from 300 mg to 2,000 mg and the MAD portion evaluated 300
RHEA-AI
negative
11/29/22 7:00 AM
Nasdaq : AVIR
clinical trialcovid-19
Atea Pharmaceuticals Announces First Patient Dosed in SUNRISE-3 Phase 3 Registrational Trial of Bemnifosbuvir, an Investigational Oral Antiviral for the Treatment of COVID-19
Global Study to Evaluate Bemnifosbuvir as Monotherapy and in Combination in Non-Hospitalized Patients at High Risk of Disease Progression, Regardless of Vaccination Status Phase 3 Evaluation of Bemnifosbuvir Supported by Clinical Data from Late-Stage MORNINGSKY Trial and Prior Studies
RHEA-AI
neutral
11/22/22 10:00 AM
Nasdaq : CMCSA
covid-19
Comcast RISE Reaches Program’s Goal of Supporting 13,000 Small Businesses Hardest Hit by COVID-19
Comcast Corporation announced today that Comcast RISE, an initiative created in 2020 to help strengthen and empower small businesses hard hit by COVID-19, has met its goal of supporting 13,000 small businesses nationwide by the program’ s close at the end of 2022.. A study from the National Bureau of Economic Research cited that Black-owned small businesses...
RHEA-AI
very positive
11/22/22 9:20 AM
OTC : RVVTF
clinical trialcovid-19
Revive Therapeutics Announces FDA Recommendation for Type C Meeting to Discuss Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19
Revive Therapeutics Ltd. (“Revive” or the “Company”) (OTCQB: RVVTF) (CSE: RVV) (FRANKFURT:31R), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, announced today that the U.S.
RHEA-AI
neutral
11/17/22 7:00 AM
Nasdaq : IVVD
partnershipclinical trialcovid-19
Invivyd Announces Partnership With Population Health Partners to Accelerate Clinical Development in Infectious Diseases Including COVID-19
-Broad partnership will strengthen Invivyd’s development platform and organizational capabilities towards acceleration of NVD200 clinical program and future engineered antibodies for COVID-19 and beyond- - Population Health Partners to integrate best-in-class capabilities to drive speed and
RHEA-AI
neutral
11/16/22 6:30 PM
Nasdaq : BNTX
covid-19
Pfizer and BioNTech Advance Next-Generation COVID-19 Vaccine Strategy with Study Start of Candidate Aimed at Enhancing Breadth of T cell Responses and Duration of Protection
NEW YORK and MAINZ, GERMANY, NOVEMBER 16, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced that the companies have initiated a Phase 1 study to evaluate the safety, tolerability and immunogenicity of a next generation COVID-19 vaccine candidate that aims to enhance
RHEA-AI
negative
11/15/22 9:30 AM
AMEX : SSY
earningscovid-19low float
SunLink Health Systems, Inc. Announces Fiscal 2023 First Quarter and COVID-19 Update
SunLink Health Systems, Inc. today announced a loss from continuing operations of $1,544,000 for its first fiscal quarter ended September 30, 2022 compared to earnings from continuing operations of $2,006,000 for the fourth fiscal quarter ended September 30, 2021. Net loss for the quarter ended September 30, 2022 was a loss of $1,558,000 compared to net...
RHEA-AI
negative
11/10/22 9:45 AM
Nasdaq : BNTX
covid-19
Pfizer and BioNTech Receive Positive CHMP Opinion for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine Booster for Children 5 Through 11 Years of Age in European Union
NEW YORK and MAINZ, GERMANY, November 10, 2022 — Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) today announced a booster dose of their Omicron BA.4/BA.5-adapted bivalent COVID-19 vaccine (COMIRNATY ® Original/Omicron BA.4/BA.5 5/5-µg) has been recommended for marketing authorization by the
RHEA-AI
neutral
11/09/22 8:55 PM
Nasdaq : VERU
covid-19
Veru Provides Update on FDA Advisory Committee Meeting Regarding Emergency Use Authorization of Sabizabulin to Treat Hospitalized COVID-19 Patients at High Risk for Acute Respiratory Distress Syndrome
Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for COVID-19 and other viral ARDS-related diseases and for oncology, announces the results of today’s meeting of the U.S. Food and Drug Administration’s (FDA)
RHEA-AI
negative
11/09/22 7:00 AM
Nasdaq : ENTA
clinical trialcovid-19low float
Enanta Pharmaceuticals Initiates SPRINT, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19
Enanta Pharmaceuticals, Inc., a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections, today announced the initiation of SPRINT, a Phase 2 clinical trial of EDP-235, Enanta’ s lead oral, 3 CL protease inhibitor, in non-hospitalized, symptomatic adults with mild or moderate COVID-19. The study is designed to...
RHEA-AI
neutral
11/07/22 4:05 PM
NYSE : QGEN
covid-19
QIAGEN Exceeds Outlook for Q3 2022 with 18% CER Sales Growth in Non-COVID Product Portfolio and Raises Full-Year 2022 Outlook
Q3 2022: Net sales of $500 million; diluted EPS of $0.36 and adjusted diluted EPS of $0.53 Net sales at CER of $533 million vs. outlook for at least $510 million CER, adjusted diluted EPS of $0.55 CER vs. outlook for at least $0.48 CER 18% CER growth in non-COVID product portfolio to $417 million First nine months 2022 operating cash flow up 34% to $591 million, while...
RHEA-AI
positive
11/04/22 6:48 AM
Nasdaq : BNTX
clinical trialcovid-19
Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
Bivalent booster elicited approximately 4-fold higher neutralizing antibody titers against Omicron BA.4/BA.5 sublineages compared to the original COVID-19 vaccine in individuals older than 55 years of age One-month after a 30-µg booster dose of the bivalent vaccine, Omicron BA.4/BA.5-neutralizing
RHEA-AI
neutral
11/04/22 6:47 AM
NYSE, Nasdaq : PFE, BNTX
clinical trialcovid-19
Pfizer and BioNTech Announce Updated Clinical Data for Omicron BA.4/BA.5-Adapted Bivalent Booster Demonstrating Substantially Higher Immune Response in Adults Compared to the Original COVID-19 Vaccine
Pfizer Inc. and BioNTech SE today announced updated data from a Phase 2/ 3 clinical trial demonstrating a robust neutralizing immune response one-month after a 30- µg booster dose of the companies’ Omicron BA.4/BA. 5- adapted bivalent COVID-19 vaccine. “As we head into the holiday season, we hope these updated data will encourage people...
RHEA-AI
neutral
11/03/22 3:20 AM
Nasdaq : BPTS
clinical trialcovid-19low float
Biophytis Reports Positive Post-hoc Analysis of The Phase 2-3 COVA Clinical Study Strongly Supporting Therapeutic Potential of Sarconeos (BIO101) In COVID-19
A reduction in the risk of early death or respiratory failure at day 28 of 45% in the Intent-To-Treat (ITT) population and 53% in the Per Protocol (PP) population A reduction in the risk of death at day 90 of 43% in the ITT population and 70% in the PP population The start of regulatory development
RHEA-AI
negative
10/27/22 9:04 AM
Nasdaq : DYAI
clinical trialcovid-19low float
Dyadic Receives Regulatory Approval to Initiate Phase 1 Clinical Trial to Demonstrate Clinical Safety and Efficacy in Humans for DYAI-100 COVID-19 Recombinant Protein RBD Booster Vaccine Candidate
Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial platforms to address the growing demand for global protein production and unmet
RHEA-AI
very positive
10/26/22 9:00 AM
NYSE : RAD
covid-19
Costumes, Candy, and Vaccinations – Rite Aid Shares Reasons to Add Flu and COVID-19 Vaccinations to Your Halloween Check List
As the U.S. Centers for Disease Control& Prevention warns of early increases in seasonal influenza cases, Rite Aid addresses common misperceptions about vaccination and stresses the importance of staying up to date on flu and COVID-19 vaccinations before Halloween. “People are looking forward to celebrating Halloween and the upcoming holiday season,” says...
RHEA-AI
neutral
10/26/22 2:00 AM
NYSE : BMY
covid-19
New Zeposia (ozanimod) Data Highlight COVID-19 Outcomes and Preservation of Long-Term Cognitive Function from Separate Analyses in Patients with Relapsing Forms of Multiple Sclerosis
Bristol Myers Squibb today announced new retrospective analyses on serologic responses and clinical outcomes with COVID-19 vaccination in participants treated with Zeposia from the ongoing Phase 3 DAYBREAK open-label extension study in relapsing multiple sclerosis. “These data are of clinical importance for physicians treating multiple sclerosis,...
RHEA-AI
neutral